MAP2K7 and amyotrophic lateral sclerosis: However, recent data leveraging transcriptomics and proteomics from post-mortem brain samples and rodent models carrying known key ALS genes has supported that trametinib, and RAS/RAF/MAPK inhibition more broadly, as an ALS therapeutic candidate.55 In other words, we only found genetic support for BRAFi as opposed to downstream MEK inhibition but existing literature supports that also targeting MEK may be therapeutically useful.55